Drugs / Osalmid
Osalmid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03670173 | Oct 2018 → May 2021 | plasma cell myeloma | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osalmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03670173 ↗ |
| Known as | L-1718 | ChEMBL registry synonym — accepted as the source's own label CHEMBL389507 ↗ |
| Known as | NSC-93960 | ChEMBL registry synonym — accepted as the source's own label CHEMBL389507 ↗ |
| Known as | Osalmida | ChEMBL registry synonym — accepted as the source's own label CHEMBL389507 ↗ |
| Known as | Osalmide | ChEMBL registry synonym — accepted as the source's own label CHEMBL389507 ↗ |
| Modality | Small molecule | — CHEMBL389507 ↗ |